Editorial Comment

Journal of Urology

Volumn 182, Issue 5, 2009, Pages 2278-2279

  Catalona, William J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; HIGH RISK PATIENT; PRIORITY JOURNAL; PROSTATE CANCER; UNITED STATES; DISEASE COURSE; HEALTH SURVEY; HUMAN; MALE; METHODOLOGY; NOTE; PATHOLOGY; PROSTATE TUMOR; PROSTATECTOMY;

DISEASE PROGRESSION; HUMANS; MALE; POPULATION SURVEILLANCE; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 70350433911     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.07.107     Document Type: Note

References (8)

1. Johansson J.E., Andren O., Andersson S.O., et al. Natural history of early, localized prostate cancer. JAMA 291 (2004) 2713
2. Draisma G., Etzioni R., Tsodikov A., et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 101 (2009) 374
3. Graif T., Loeb S., Roehl K.A., et al. Under diagnosis and over diagnosis of prostate cancer. J Urol 178 (2007) 88
4. Barocas D.A., Cowan J.E., Smith Jr. J.A., et al. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance?. An analysis of the CaPSURE database. J Urol 180 (2008) 1330
5. Griffin C.R., Yu X., Loeb S., et al. Pathological features after radical prostatectomy in potential candidates for active monitoring. J Urol 178 (2007) 860
6. Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol 24 (2006) 46
7. Whitmore Jr. W.F. Natural history of low-stage prostatic cancer and the impact of early detection. Urol Clin North Am 17 (1990) 689
8. Schroder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360 (2009) 1320